BerGenBio
Clinical-stage biopharma that developed selective AXL kinase inhibitors for cancer.
BGBIO | OL
Overview
Corporate Details
- ISIN(s):
- NO0012921180 (+2 more)
- LEI:
- 213800TYYFXKYF3V2A23
- Country:
- Norway
- Address:
- MØLLENDALSBAKKEN 9, 5009 BERGEN
- Website:
- https://www.bergenbio.com/
- Sector:
- Manufacturing
Description
BerGenBio was a clinical-stage biopharmaceutical company focused on developing first-in-class selective AXL kinase inhibitors. The company's therapeutic candidates targeted AXL as a potential cornerstone of therapy for aggressive, advanced, and treatment-resistant cancers. In October 2025, BerGenBio completed a merger with Oncoinvent ASA, and the combined entity was renamed Oncoinvent.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2020-08-18 05:02 |
BERGENBIO ASA: RESULTS FOR THE SECOND QUARTER AND FIRST HALF OF 2020
|
English | 248.9 KB | ||
| 2020-08-18 05:02 |
BERGENBIO ASA: RESULTS FOR THE SECOND QUARTER AND FIRST HALF OF 2020
|
English | 10.0 KB | ||
| 2020-08-18 05:01 |
BerGenBios Bemcentinib oppfyller effektendepunktet i BERGAMO fase II-forsøk hos…
|
Norwegian | 297.0 KB | ||
| 2020-08-18 05:01 |
BerGenBios Bemcentinib oppfyller effektendepunktet i BERGAMO fase II-forsøk hos…
|
Norwegian | 7.7 KB | ||
| 2020-08-18 05:00 |
BerGenBio's Bemcentinib Meets Efficacy Endpoint in BERGAMO Phase II Trial with …
|
English | 232.0 KB | ||
| 2020-08-18 05:00 |
BerGenBio's Bemcentinib Meets Efficacy Endpoint in BERGAMO Phase II Trial with …
|
English | 7.6 KB | ||
| 2020-08-10 06:02 |
BerGenBio ASA: Primary Insider notification
|
English | 672 bytes | ||
| 2020-08-10 05:00 |
BERGENBIO ASA: Invitation to second quarter 2020 results webcast presentation
|
English | 2.7 KB | ||
| 2020-08-05 14:38 |
BerGenBio ASA: Primary Insider notification
|
English | 671 bytes | ||
| 2020-08-04 15:19 |
BerGenBio ASA: Primary Insider notification
|
English | 671 bytes | ||
| 2020-08-03 14:44 |
BerGenBio ASA: Primary Insider notification
|
English | 671 bytes | ||
| 2020-07-30 14:33 |
BerGenBio ASA: Primary Insider notification
|
English | 671 bytes | ||
| 2020-07-29 14:36 |
BerGenBio ASA: Primary Insider notification
|
English | 665 bytes | ||
| 2020-07-29 10:55 |
BerGenBio ASA: Primary Insider notification
|
English | 671 bytes | ||
| 2020-07-28 15:35 |
UPDATE ON BEMCENTINIB'S INVOLVEMENT IN POTENTIAL TREATMENT OF COVID-19 PANDEMIC
|
English | 222.1 KB |
Automate Your Workflow. Get a real-time feed of all BerGenBio filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for BerGenBio
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for BerGenBio via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
